WO1996004265A1 - 2,6-DIDEOXY-2,3-DIDEHYDRO-6-THIO DERIVATIVES OF α-D-NEURAMINIC ACID - Google Patents
2,6-DIDEOXY-2,3-DIDEHYDRO-6-THIO DERIVATIVES OF α-D-NEURAMINIC ACID Download PDFInfo
- Publication number
- WO1996004265A1 WO1996004265A1 PCT/AU1995/000470 AU9500470W WO9604265A1 WO 1996004265 A1 WO1996004265 A1 WO 1996004265A1 AU 9500470 W AU9500470 W AU 9500470W WO 9604265 A1 WO9604265 A1 WO 9604265A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- thio
- formula
- hydrogen
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 112
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- -1 SOOH Chemical group 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 150000001409 amidines Chemical group 0.000 claims description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical group CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical group C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims description 2
- 229910006069 SO3H Inorganic materials 0.000 claims description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 34
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 102000005348 Neuraminidase Human genes 0.000 description 10
- 108010006232 Neuraminidase Proteins 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- 241000712469 Fowl plague virus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003527 tetrahydropyrans Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229940029284 trichlorofluoromethane Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- YWYHGNUFMPSTTR-UHFFFAOYSA-N 1-methyl-4-(4-methylphenoxy)benzene Chemical class C1=CC(C)=CC=C1OC1=CC=C(C)C=C1 YWYHGNUFMPSTTR-UHFFFAOYSA-N 0.000 description 1
- GWEATQMXNIFWCP-UHFFFAOYSA-N 1H-pyrazole-5-carboximidamide hydrochloride Chemical compound Cl.NC(=N)C=1C=CNN=1 GWEATQMXNIFWCP-UHFFFAOYSA-N 0.000 description 1
- JINJZWSZQKHCIP-UFGQHTETSA-N 2-deoxy-2,3-dehydro-N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO JINJZWSZQKHCIP-UFGQHTETSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- CERZMXAJYMMUDR-LSRLBZCKSA-N alpha-neuraminic acid Chemical compound N[C@@H]1[C@@H](O)C[C@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-LSRLBZCKSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical class OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229940078487 nickel acetate tetrahydrate Drugs 0.000 description 1
- OINIXPNQKAZCRL-UHFFFAOYSA-L nickel(2+);diacetate;tetrahydrate Chemical compound O.O.O.O.[Ni+2].CC([O-])=O.CC([O-])=O OINIXPNQKAZCRL-UHFFFAOYSA-L 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-L oxaloacetate(2-) Chemical compound [O-]C(=O)CC(=O)C([O-])=O KHPXUQMNIQBQEV-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
Definitions
- This invention relates to a new class of chemical compounds and to their use in medicine.
- the invention concerns new 2,6-dideoxy-2,3-didehydro-6-thio derivatives of ⁇ -D-neuraminic acid, methods for their preparation, pharmaceutical formulations thereof and their use as anti-viral agents.
- Enzymes with the ability to cleave N-acetyl neuraminic acid ( ⁇ A ⁇ A), also known as sialic acid, from other sugars are present in many microorganisms. These include bacteria such as Vibrio cholerae, Clostridium perfringans , Streptococcus pneumoniae , and Arthrobacter sialophilus , and viruses such as influenza virus,
- neuraminidase is also known as sialidase.
- neuraminidase-possessing organisms are major pathogens of man and/or animals, and some, such as influenza virus, Newcastle disease virus, and fowl plague virus, cause diseases of enormous economic
- neuraminidase inhibitors are analogues of neuraminic acid, such as 2-deoxy-2,3 -dehydro-N-acetylneuraminic acid (DANA) and its derivatives. See, e.g., Meindl et al., Virology, 1974 58 457-463. The most active of these is 2-deoxy-2,3- dehydro-N- trifluoroacetyl-neuraminic acid (FANA), which inhibits multi-cycle replication of influenza and
- WO 91/16320 describes a number of analogues of DANA. The entire disclosure of this specification is herein incorporated by reference. The compounds disclosed in WO 91/16320 are active both in vitro and in vivo against viral neuraminidase, and are useful in the treatment of influenza.
- the invention therefore provides in a first aspect compounds of formula (I)
- R 1 is COOH, P(O)(OH) 2 , NO 2 , SOOH,
- R 2 and R 3 are OH, (alk) x NR 6 R 7 , CN or N 3 , and the other is hydrogen, where alk is unsubstituted or substituted methylene, and x is 0 or 1, with the proviso that when R 2 or R 3 is OH, R 1 cannot be COOH;
- R 4 is methyl, in which one or more hydrogens is optionally replaced by a substituted or unsubstituted C 1-4 alkyl or aryl group, or by a halogen;
- R 5 is CHOR 9 CHOR 9 CH 2 OR 9 ;
- R 6 is hydrogen, C 1-6 alkyl (e.g. methyl, ethyl), allyl, aryl (e.g. phenyl), aralkyl (e.g. phenC 1-3 alkyl such as benzyl), amidine, NR 7 R 8 , or an unsaturated or saturated ring containing one or more heteroatoms such as nitrogen, oxygen or sulphur;
- R 7 is hydrogen, C 1-6 alkyl (e.g. methyl, ethyl), or allyl, or NR 6 R 7 forms an optionally substituted 5 or 6 membered ring optionally containing one or more additional heteroatoms such as nitrogen, oxygen or sulphur, or R 6 and R 7 may be the same; and
- R 8 is hydrogen or C 1-6 alkyl
- each R 9 is the same or different, and is hydrogen; an acyl group having 1 to 4 carbon atoms; a linear or cyclic alkyl group having 1 to 6 carbon atoms, or a halogen-substituted analogue thereof; an allyl group or an unsubstituted aryl group; or an aryl substituted by a halogen, an OH group, an NO 2 group, an NH 2 group or a COOH group;
- substituents for example the group R 6 in the substituent R 1
- substituents may themselves bear substituents conventionally associated in the art of pharmaceutical chemistry with such substituents.
- R 1 is COOH
- R 2 is H
- R 3 is NR 6 R 7 , more preferably NH 2 or guanidino.
- R 4 is methyl or halogen-substituted methyl, e.g. FCH 2 , F 2 CH, CF 3 , More preferably R 4 is methyl.
- R 9 is hydrogen or acetyl.
- a preferred class of compounds of formula (I) are those of formula (la)
- R 3 , R 4 and R 5 and X are as defined for formula (I) and pharmaceutically acceptable salts and derivatives thereof.
- C 1-4 alkyl as used herein includes both straight chain (e.g. methyl, ethyl) and branched chain (e.g.
- the invention provides a compound of formula (II),
- R 3 is NH 2 or NHC(NH) (NH 2 ), and physiologically acceptable derivatives and solvates, such as hydrates, thereof.
- Representative compounds within this embodiment include 5-acetamido-4-azido-2,3,4,5,6-pentadeoxy-6-thio-D- glycero-D-galacto-non-2-endopyranosonic acid, 5-acetamido4-amino-2,3,4,5,6-pentadeoxv-6-thio-D-glycero-D-galacto- non-2-endopyranosonic acid, and 5-acetamido-4-guanidino- 2,3,4,5,6-pentadeoxy-6-thio-D-glycero-P-galacto-non-2- endopyranosonic acid, and physiologically acceptable salts and esters thereof.
- pharmaceutically acceptable derivative any pharmaceutically acceptable salt, ester or salt of such ester of the compounds of formula (I) or any other compound which upon administration to the recipient is capable of providing, directly or indirectly, a compound of formula (I) or an anti-virally active metabolite or residue thereof. It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds.
- compounds of interest include C-1 alkyl (such as methyl, ethyl or propyl e.g. isopropyl) or aryl (e.g. phenyl, benzyl) esters of the compounds of formula (I), C-7 or C-9 esters of compounds of formula (I) such as acetyl esters thereof and C-7 or C-9 ethers such as phenyl ethers, benzyl ethers, and p-tolyl ethers and acylated amino derivatives such as formyl, acetamido.
- C-1 alkyl such as methyl, ethyl or propyl e.g. isopropyl
- aryl e.g. phenyl, benzyl
- C-7 or C-9 esters of compounds of formula (I) such as acetyl esters thereof
- C-7 or C-9 ethers such as phenyl ethers, benzyl ethers, and p-
- acids and bases examples include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicyclic,
- Other acids such as oxalic, while not in themselves pharmaceutically
- Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g.
- the compounds of formula (I) are, generically, substituted analogues of 2,6- dideoxy-2,3-didehydro-6-thio-N-acetylneuraminic acid; thus the following names are synonymous:- 5-Acetamido-2,6-anhydro-4-substituent-3,4,5,6- tetradeoxy-6-thio-D-glycero-D-galacto-non-2-enonic acid
- the compounds of formula (I) possess anti-viral activity.
- these compounds are inhibitors of viral neuraminidase in particular neuraminidase of
- orthomyxoviruses and paramyxoviruses for example the viral neuraminidase of influenza A and B, parainfluenza, mumps and Newcastle disease.
- a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof for use as an active therapeutic agent, in particular as an anti-viral agent, for example in the treatment of orthomyxovirus and
- a method for the treatment of a viral infection for example orthomyxovirus and paramyxovirus infections in a mammal, including man, comprising the step of
- prophylaxis as well as to the treatment of established infections or symptoms.
- a suitable dose will be in the range of from about 0.1 to 750 mg/kg of body weight per day, preferably in the range of 0.5 to 60 mg/kg/day, most preferably in the range of 1 to 20 mg/kg/day.
- Treatment is preferably commenced before or at the time of infection and continued until virus is no longer present in the respiratory tract.
- the compounds are also effective when given post-infection, for example after the appearance of established symptoms.
- treatment is given 1-4 times daily and continued for 3-7 days, e.g. 5 days post infection,
- the desired dose may be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more subdoses per day.
- the compound is conveniently administered in unit dosage form, for example containing 1 to 1500 mg,
- a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.
- the invention thus further provides a
- the carrier (s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not being deleterious to the recipient thereof.
- the pharmaceutical formulations may be in the form of conventional formulations for the intended mode of administration.
- compositions include those
- formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
- compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
- the tablets may be coated according to methods well known in the art.
- Oral liquid preparations may be in the form of, for example, aqueous or oily
- suspensions solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.
- the compound according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in
- the composition may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile,
- the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be
- aqueous or oily base formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
- Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or
- tragacanth pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- inert base such as gelatin and glycerin or sucrose and acacia
- mouthwashes comprising the active ingredient in a suitable liquid carrier.
- compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
- suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- the neuraminidase inhibitors of general formula (I) may be administered by any of the methods and formulations employed in the art for intranasal administration, or administration by inhalation or
- the compounds may be administered in the form of a solution or a suspension or as a dry powder.
- Solutions and suspensions will generally be aqueous for example prepared from water alone (for example sterile or pyrogen-free water) or water and a
- physiologically acceptable co-solvent for example ethanol, propylene glycol, polyethylene glycols such as PEG 400.
- Such solutions or suspensions may additionally contain other excipients, for example preservatives (such as benzalkonium chloride), solubilising agents/surfactants such as polysorbates (e.g. Tween 80, Span 80, benzalkonium chloride), buffering agents, isotonicity-adjusting agents (for example sodium chloride), absorption enhancers and viscosity enhancers.
- Suspensions may additionally contain suspending agents (for example microcrystalline cellulose, carboxymethyl cellulose sodium).
- Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
- the formulations may be
- a means of dose metering is desirably provided.
- a dropper or pipette this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension.
- a spray this may be achieved for example by means of a metering atomising spray pump.
- Intranasal administration may also be achieved by means of an aerosol formulation in which the compound is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example
- a suitable propellant such as a chlorofluorocarbon (CFC), for example
- the aerosol may conveniently also contain a
- the dose of drug may be controlled by provision of a metered valve.
- Solutions or suspensions are described above may also be administered to the respiratory tract via the mouth, for example, by means of a nebuliser.
- the compounds may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- PVP polyvinylpyrrolidine
- the powder carrier will form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form for example in capsules or cartridges of e.g. gelatin or blister packs from which the powder may be administered by means of an inhaler.
- the compound In the formulations for administration to the respiratory tract, the compound will generally have a small particle size, for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronisation.
- the formulation is suitable for intranasal administration, and may be presented as a liquid spray or dispersible powder or in the form of drops.
- Drops may be formulated with an aqueous or non- aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents.
- Liquid sprays are conveniently delivered from pressurised packs, which may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane,
- dichlorotetrafluoroethane carbon dioxide or other suitable gas.
- formulations adapted to give sustained release of the active ingredient may be employed.
- the compounds of the invention may also be used in combination with other therapeutic agents, for example other anti-infective agents.
- the compounds of the invention may be employed with other anti-viral agents.
- the invention thus provides in a further aspect a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof together with another therapeutically active agent, in particular an anti-viral agent.
- compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier therefor comprise a further aspect of the invention.
- Suitable therapeutic agents for use in such combinations include other anti-infective agents, in particular anti-bacterial and anti-viral agents such as those used to treat respiratory infections.
- anti-infective agents in particular anti-bacterial and anti-viral agents such as those used to treat respiratory infections.
- anti-bacterial and anti-viral agents such as those used to treat respiratory infections.
- other compounds effective against influenza viruses such as amantadine, rimantadine and ribavirin, may be included in such combinations.
- each compound may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
- the dose of each compound may either be the same as or differ from that employed when each compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
- the compounds of formula (I) and their pharmaceutically acceptable salts and derivatives may be prepared by any method known in the art for the preparation of compounds of analogous structure.
- the compounds of formula (I) may be prepared by the methods described below which form a further aspect of the
- the invention provides a method for the preparation of a compound of formula (I), comprising the steps of subjecting a 2,3,5,6- tetradeoxy-4',5'-dihydro-2'-methyloxazolo[5,4-D-6-thio-D- glycero- ⁇ -D-talo-non-2-enopyranosonate to hydrolysis to give a compound of general formula (III),
- R 1 , R 4 and R 5 are as defined in general formula (I), and OL is a leaving group such as a sulphonic acid residue, for example tosyl, mesyl, or trifluoromesyl, or a protected derivative of a compound of formula (III), and reacting the compound of formula (III) with an appropriate nucleophile, for example azide, cyanide, an appropriate carbanion, or thioacetate.
- an appropriate nucleophile for example azide, cyanide, an appropriate carbanion, or thioacetate.
- Compounds of formula (I) may also be prepared from other compounds of formula (I) by interconversion.
- the protecting group may be removed at any convenient subsequent stage in the reaction sequence.
- the protecting groups used in the preparation of compounds of formula (I) may be used in a conventional manner. See for example 'Protective Groups in Organic Chemistry', Ed. J.F.W. McOmie (Plenum Press, 1973) or
- Conventional amino protecting groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups, and acyl groups such as
- Hydroxy groups may be protected, for example, by aralkyl groups, such as benzyl, diphenylmethyl or
- triphenylmethyl groups acyl groups, such as acetyl
- silicon protecting groups such as trimethylsilyl groups; or as tetrahydropyran derivatives.
- an aralkyl group such as benzyl
- a catalyst e.g. palladium on charcoal
- an acyl group such as N-benzyloxycarbonyl may be removed by hydrolysis with, for example, hydrogen bromide in acetic acid, or by reduction, for example by catalytic
- silicon protecting groups may be removed, for example, by treatment with fluoride ion;
- tetrahydropyran groups may be cleaved by hydrolysis under acidic conditions.
- a compound of the invention for example as an acid addition salt
- this may be achieved by treating the free base of general formula (I) with an appropriate acid, preferably with an equivalent amount, or with creatinine sulphate in a
- Suitable solvent e.g. aqueous ethanol.
- triphenylphosphine (9.1 g; 34.7 mmol) in dry
- compound 4 can be deacetylated using a solution of sodium methoxide in methanol, in similar yield, following the literature method of Brossmer and Mack (Tetrahedron Letters, 1981 22 933).
- This compound was prepared from the triol 5 following the literature method of Brossmer and Mack (Tetrahedron Letters, 1987 28 191).
- the oxazoline 11 (1.04 g; 2.42 mmol) was treated with azidotrimethylsilane (0.96 mL; 7.26 mmol) in 2-methyl- 2-propanol (10 mL) at 75 - 80°C for 48 h.
- the solution was cooled, added to saturated sodium bicarbonate, and after 1 h, extracted with ethyl acetate (3 x 50 mL). The extracts were dried (Na 2 SO 4 ) and solvent removal gave a syrup
- the amine hydrochloride 13 was characterised as its peracetate. Thus, the azide 12 (47.5 mg; 0.10 mmol) was treated with zinc dust and 2N HCl as described above. The crude amine hydrochloride 13 was then treated with acetic anhydride (1 mL) and concentrated sulphuric acid
- Sialidase activity was assayed using the fluorim ⁇ tric assay of Potier et al (Anal. Biochem., (1979), 94 287), as modified by Chong et al (Biochim. Biophys.
- This compound was found to be a slow binding inhibitor.
- compositions according to the invention are representative of compositions according to the invention:
- Lactose 60 .0 These formulations are prepared by admixture of the active ingredient and excipients by conventional pharmaceutical methods.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides 2,6-dideoxy-2,3-didehydro-6-thio derivatives of α-D-neuraminic acid. Methods for preparation of the compounds of the invention, pharmaceutical formulations comprising the compounds, and use of the compounds as anti-viral agents are also disclosed and claimed.
Description
2,6-DIDEOXY-2,3-DIDEHYDRO-6-THIO DERIVATIVES
OF α-D-NEURAMINIC ACID
This invention relates to a new class of chemical compounds and to their use in medicine. In particular the invention concerns new 2,6-dideoxy-2,3-didehydro-6-thio derivatives of α-D-neuraminic acid, methods for their preparation, pharmaceutical formulations thereof and their use as anti-viral agents.
Enzymes with the ability to cleave N-acetyl neuraminic acid (ΝAΝA), also known as sialic acid, from other sugars are present in many microorganisms. These include bacteria such as Vibrio cholerae, Clostridium perfringans , Streptococcus pneumoniae , and Arthrobacter sialophilus , and viruses such as influenza virus,
parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague virus, said Sendai virus. Host of these viruses are of the orthomyxovirus or paramyxovirus groups, and carry a neuraminidase activity on the surface of the virus particles. It is noted that neuraminidase is also known as sialidase.
Many of the neuraminidase-possessing organisms are major pathogens of man and/or animals, and some, such as influenza virus, Newcastle disease virus, and fowl plague virus, cause diseases of enormous economic
importance.
It has long been thought that inhibitors of neuraminidase activity might prevent infection by
neuraminidase-bearing viruses. Most of the known
neuraminidase inhibitors are analogues of neuraminic acid, such as 2-deoxy-2,3 -dehydro-N-acetylneuraminic acid (DANA) and its derivatives. See, e.g., Meindl et al., Virology, 1974 58 457-463. The most active of these is 2-deoxy-2,3- dehydro-N- trifluoroacetyl-neuraminic acid (FANA), which inhibits multi-cycle replication of influenza and
parainfluenza viruses in vitro . See Palese et al, Virology 1974 59 490-498.
Our earlier international application Publication No. WO 91/16320 describes a number of analogues of DANA. The entire disclosure of this specification is herein incorporated by reference. The compounds disclosed in WO 91/16320 are active both in vitro and in vivo against viral neuraminidase, and are useful in the treatment of influenza.
We have now found further compounds which fall generally within the scope of the compounds described and claimed in WO 91/16320, but which are not specifically disclosed therein. These compounds have particularly advantageous properties. Summary of the Invention
The invention therefore provides in a first aspect compounds of formula (I)
SO3H, tetrazol, CH2CHO, CHO, or CH(CHO)2; one of R2 and R3 is OH, (alk)xNR6R7, CN or N3, and the other is hydrogen, where alk is unsubstituted or substituted methylene, and x is 0 or 1, with the proviso that when R2 or R3 is OH, R1 cannot be COOH;
R4 is methyl, in which one or more hydrogens is optionally replaced by a substituted or unsubstituted C1-4alkyl or aryl group, or by a halogen;
R5 is CHOR9CHOR9CH2OR9 ;
R6 is hydrogen, C1-6alkyl (e.g. methyl, ethyl), allyl, aryl (e.g. phenyl), aralkyl (e.g. phenC1-3alkyl such as benzyl), amidine, NR7R8, or an unsaturated or saturated ring containing one or more heteroatoms such as nitrogen,
oxygen or sulphur;
R7 is hydrogen, C1-6alkyl (e.g. methyl, ethyl), or allyl, or NR6R7 forms an optionally substituted 5 or 6 membered ring optionally containing one or more additional heteroatoms such as nitrogen, oxygen or sulphur, or R6 and R7 may be the same; and
R8 is hydrogen or C1-6alkyl; and
each R9 is the same or different, and is hydrogen; an acyl group having 1 to 4 carbon atoms; a linear or cyclic alkyl group having 1 to 6 carbon atoms, or a halogen-substituted analogue thereof; an allyl group or an unsubstituted aryl group; or an aryl substituted by a halogen, an OH group, an NO2 group, an NH2 group or a COOH group;
and pharmaceutically acceptable salts of the compounds of formula (I) and pharmaceutically acceptable derivatives thereof.
In the compounds of formula (I) the substituents (for example the group R6 in the substituent R1), may themselves bear substituents conventionally associated in the art of pharmaceutical chemistry with such substituents.
Preferably R1 is COOH, and R2 is H.
Preferably R3 is NR6R7, more preferably NH2 or guanidino.
Preferably R4 is methyl or halogen-substituted methyl, e.g. FCH2, F2CH, CF3, More preferably R4 is methyl.
Preferably R9 is hydrogen or acetyl.
A preferred class of compounds of formula (I) are those of formula (la)
wherein R3, R4 and R5 and X are as defined for formula (I) and pharmaceutically acceptable salts and derivatives thereof.
C1-4alkyl as used herein includes both straight chain (e.g. methyl, ethyl) and branched chain (e.g.
isopropyl, t-butyl) alkyl groups.
In a particularly preferred embodiment the invention provides a compound of formula (II),
wherein R3 is NH2 or NHC(NH) (NH2), and physiologically acceptable derivatives and solvates, such as hydrates, thereof.
Representative compounds within this embodiment include 5-acetamido-4-azido-2,3,4,5,6-pentadeoxy-6-thio-D- glycero-D-galacto-non-2-endopyranosonic acid, 5-acetamido4-amino-2,3,4,5,6-pentadeoxv-6-thio-D-glycero-D-galacto- non-2-endopyranosonic acid, and 5-acetamido-4-guanidino- 2,3,4,5,6-pentadeoxy-6-thio-D-glycero-P-galacto-non-2- endopyranosonic acid, and physiologically acceptable salts and esters thereof.
The person skilled in the art will understand that substituents at the 4-position can be interconverted as described in WO 91/16320.
By pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, ester or salt of such ester of the compounds of formula (I) or any other compound which upon administration to the recipient is capable of providing, directly or indirectly, a compound of formula (I) or an anti-virally active metabolite or residue thereof.
It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds. Of
particular interest as such derivatives are compounds modified at the C-1 carboxyl function, the C-7 or C-9 hydroxyl functions or at amino groups. Thus compounds of interest include C-1 alkyl (such as methyl, ethyl or propyl e.g. isopropyl) or aryl (e.g. phenyl, benzyl) esters of the compounds of formula (I), C-7 or C-9 esters of compounds of formula (I) such as acetyl esters thereof and C-7 or C-9 ethers such as phenyl ethers, benzyl ethers, and p-tolyl ethers and acylated amino derivatives such as formyl, acetamido.
It will be appreciated by those skilled in the art that the pharmaceutically acceptable derivatives of the compounds of formula (I) may be derivatised at more than one position.
Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from
pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicyclic,
succinic, toluene-p-sulphonic, tartaric, acetic, citric, methane-sulphonic, formic, benzoic, malonic, naphthalene-2- sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically
acceptable, may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g.
magnesium), ammonium and (NR4)+ (wherein R is C1-4alkyl) salts.
References hereinafter to a compound of the invention include the compounds of formula (I) and
pharmaceutically acceptable salts and derivatives thereof.
It will be appreciated by those skilled in the art that the nomenclature of the compounds of formula (I) can be defined in a number of ways. The compounds of formula (I) are, generically, substituted analogues of 2,6- dideoxy-2,3-didehydro-6-thio-N-acetylneuraminic acid; thus the following names are synonymous:- 5-Acetamido-2,6-anhydro-4-substituent-3,4,5,6- tetradeoxy-6-thio-D-glycero-D-galacto-non-2-enonic acid
5-Acetamido-4-substituent-2,3,4,5,6-pentadeoxy-6- thio-D-glycero-D-gaIacto-non-2-enopyranosonic acid.
The compounds of formula (I) possess anti-viral activity. In particular these compounds are inhibitors of viral neuraminidase in particular neuraminidase of
orthomyxoviruses and paramyxoviruses, for example the viral neuraminidase of influenza A and B, parainfluenza, mumps and Newcastle disease.
There is thus provided in a further aspect of the invention a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof for use as an active therapeutic agent, in particular as an anti-viral agent, for example in the treatment of orthomyxovirus and
paramyxovirus infections.
In a further or alternative aspect there is provided a method for the treatment of a viral infection, for example orthomyxovirus and paramyxovirus infections in a mammal, including man, comprising the step of
administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof.
There is also provided in a further or alternative aspect use of a compound of the invention for the manufacture of a medicament for the treatment of a viral infection.
It will be appreciated by those skilled in the art that reference herein to treatment extends to
prophylaxis as well as to the treatment of established infections or symptoms.
It will be further appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected, but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician or veterinarian. In general, however, a suitable dose will be in the range of from about 0.1 to 750 mg/kg of body weight per day, preferably in the range of 0.5 to 60 mg/kg/day, most preferably in the range of 1 to 20 mg/kg/day.
Treatment is preferably commenced before or at the time of infection and continued until virus is no longer present in the respiratory tract. However the compounds are also effective when given post-infection, for example after the appearance of established symptoms.
Suitably treatment is given 1-4 times daily and continued for 3-7 days, e.g. 5 days post infection,
depending upon the particular compound used.
The desired dose may be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more subdoses per day.
The compound is conveniently administered in unit dosage form, for example containing 1 to 1500 mg,
conveniently 3 to 700 mg, most conveniently 5 to 70 mg of active ingredient per unit dosage form.
While it is possible that for use in therapy a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.
The invention thus further provides a
pharmaceutical formulation comprising a compound of the
formula (I) or a pharmaceutically acceptable salt or derivative thereof together with one or more
pharmaceutically acceptable carriers therefor and
optionally, other therapeutic and/or prophylactic
ingredients. The carrier (s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not being deleterious to the recipient thereof. The pharmaceutical formulations may be in the form of conventional formulations for the intended mode of administration.
Pharmaceutical formulations include those
suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including
intramuscular, sub-cutaneous and intravenous)
administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
Pharmaceutical formulations suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily
suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.
The compound according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in
ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The composition may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile,
pyrogen-free water, before use.
For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be
formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or
tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most
preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the
softened or melted carrier (s) followed by chilling and shaping in moulds.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
For administration to the respiratory tract
(including intranasal administration) according to the method of the invention, the neuraminidase inhibitors of general formula (I) may be administered by any of the methods and formulations employed in the art for intranasal administration, or administration by inhalation or
insufflation via the mouth.
Thus in general the compounds may be administered in the form of a solution or a suspension or as a dry powder.
Solutions and suspensions will generally be aqueous for example prepared from water alone (for example sterile or pyrogen-free water) or water and a
physiologically acceptable co-solvent (for example ethanol, propylene glycol, polyethylene glycols such as PEG 400).
Such solutions or suspensions may additionally contain other excipients, for example preservatives (such as benzalkonium chloride), solubilising agents/surfactants such as polysorbates (e.g. Tween 80, Span 80, benzalkonium chloride), buffering agents, isotonicity-adjusting agents (for example sodium chloride), absorption enhancers and viscosity enhancers. Suspensions may additionally contain suspending agents (for example microcrystalline cellulose, carboxymethyl cellulose sodium).
Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a
dropper, pipette or spray. The formulations may be
provided in single or multidose form. In the latter case a means of dose metering is desirably provided. In the case of a dropper or pipette this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray this may be achieved for example by means of a metering atomising spray pump.
Intranasal administration may also be achieved by means of an aerosol formulation in which the compound is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example
dichlorodifluoromethane, trichlorofluoromethane or
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. The aerosol may conveniently also contain a
surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.
Solutions or suspensions are described above may also be administered to the respiratory tract via the mouth, for example, by means of a nebuliser.
Alternatively the compounds may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). For intranasal
administration, conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g. gelatin or blister packs from which the powder may be administered by means of an inhaler.
In the formulations for administration to the respiratory tract, the compound will generally have a small particle size, for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronisation.
Preferably the formulation is suitable for intranasal administration, and may be presented as a liquid
spray or dispersible powder or in the form of drops.
Drops may be formulated with an aqueous or non- aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents. Liquid sprays are conveniently delivered from pressurised packs, which may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
When desired, formulations adapted to give sustained release of the active ingredient may be employed.
The compounds of the invention may also be used in combination with other therapeutic agents, for example other anti-infective agents. In particular the compounds of the invention may be employed with other anti-viral agents. The invention thus provides in a further aspect a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof together with another therapeutically active agent, in particular an anti-viral agent.
The combinations referred to above may conveniently be presented for use in the form of a
pharmaceutical formulation, and thus such formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefor comprise a further aspect of the invention.
Suitable therapeutic agents for use in such combinations include other anti-infective agents, in particular anti-bacterial and anti-viral agents such as those used to treat respiratory infections. For example, other compounds effective against influenza viruses, such as amantadine, rimantadine and ribavirin, may be included in such combinations.
The individual components of such combination may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
When the compounds of the invention are used with a second therapeutic agent active against the same virus, the dose of each compound may either be the same as or differ from that employed when each compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
The compounds of formula (I) and their pharmaceutically acceptable salts and derivatives may be prepared by any method known in the art for the preparation of compounds of analogous structure. In particular the compounds of formula (I) may be prepared by the methods described below which form a further aspect of the
invention.
In one preferred embodiment, the invention provides a method for the preparation of a compound of formula (I), comprising the steps of subjecting a 2,3,5,6- tetradeoxy-4',5'-dihydro-2'-methyloxazolo[5,4-D-6-thio-D- glycero-β-D-talo-non-2-enopyranosonate to hydrolysis to give a compound of general formula (III),
wherein R1, R4 and R5 are as defined in general formula (I), and OL is a leaving group such as a sulphonic acid residue, for example tosyl, mesyl, or trifluoromesyl, or a protected derivative of a compound of formula (III), and reacting the compound of formula (III) with an appropriate nucleophile, for example azide, cyanide, an appropriate carbanion, or thioacetate.
by inversion of the 4-hydroxy group by methods known in the art, for example by reaction with a Lewis acid such as BF3 etherate, followed by hydrolysis. Compounds of formula (IV) are either known in the art, or may be obtained by methods analogous to those for preparing the known
compounds referred to herein, or methods analogous to those described in WO 91/16320.
Compounds of formula (I) may also be prepared from other compounds of formula (I) by interconversion.
Thus compounds of formula (I) wherein R3 is NH2 or CH2NH2 may be prepared by reduction of the corresponding azido or cyano analogues respectively. Compounds wherein R3 is NH alkyl or guanldino may be prepared by derivatisation of the corresponding compounds wherein R3 NH2.
Some of the intermediate compounds described herein are themselves novel, and these compounds, namely methyl 3-S-acetyl-2-azido-2-deoxy-3-thio-α-D- mannopyranoside, 1,4,6-tri-O-acetyl-3-S-acetyl-2-azido-2- deoxy-3-thio-α-D-mannopyranose, methyl 5-acetamido-5,6- dideoxy-6-thio-D-glycero-β-D-galacto-non-2-ulo- pyranosonate, methyl 7,8,9-tri-0-acetyl-2,3,5,6-tetradeoxy- 4',5'-dihydro-2'-methyloxazolo[5,4-d]-6-thio-D-glycero-β-D- talo-non-2-enopyranosonate, methyl 5-acetamido-7,8,9-tri-o- acetyl-4-azido-2,3,4,5,6-pentadeoxy-6-thio-D-glycero-D- galacto-non-2-enopyranosonate, and 5-acetamido-4-ammonium- 2,3,4,5,6-pentadeoxy-6-thio-D-glycero -D-galacto-non-2- enopyranosonate, are clearly to be understood to be within the scope of this invention.
As will be appreciated by those skilled in the art, it may be necessary or desirable at any stage in the processes described herein to protect one or more sensitive groups in the molecule to prevent undesirable side
reactions; the protecting group may be removed at any convenient subsequent stage in the reaction sequence.
The protecting groups used in the preparation of compounds of formula (I) may be used in a conventional manner. See for example 'Protective Groups in Organic Chemistry', Ed. J.F.W. McOmie (Plenum Press, 1973) or
'Protective Groups in Organic Synthesis' by Theodora W.
Greene (John Wiley and Sons, 1981).
Conventional amino protecting groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups, and acyl groups such as
N-benzyloxycarbonyl or t-butoxycarbonyl. Thus, compounds of general formula (I) wherein one or both of the groups R3 and R4 represent hydrogen may be prepared by deprotection of a corresponding protected compound.
Hydroxy groups may be protected, for example, by aralkyl groups, such as benzyl, diphenylmethyl or
triphenylmethyl groups; acyl groups, such as acetyl;
silicon protecting groups, such as trimethylsilyl groups; or as tetrahydropyran derivatives.
Removal of any protecting groups present may be achieved by conventional procedures. Thus an aralkyl group, such as benzyl, may be cleaved by hydrogenolysis in the presence of a catalyst, e.g. palladium on charcoal; an acyl group such as N-benzyloxycarbonyl may be removed by hydrolysis with, for example, hydrogen bromide in acetic acid, or by reduction, for example by catalytic
hydrogenation; silicon protecting groups may be removed, for example, by treatment with fluoride ion;
tetrahydropyran groups may be cleaved by hydrolysis under acidic conditions.
Where it is desired to isolate a compound of the invention as a salt, for example as an acid addition salt,
this may be achieved by treating the free base of general formula (I) with an appropriate acid, preferably with an equivalent amount, or with creatinine sulphate in a
suitable solvent (e.g. aqueous ethanol).
The present invention is further described by the following examples which are for illustrative purposes only and should not be construed as a limitation of the
invention.
This compound was prepared following the literature method of Brossmer and Mack (Tetrahedron
Letters, 1981 22 933) without modification.
13C NMR (CDCl3; 6 (ppm) relative to TMS): 30.6, 44.8, 55.0, 64.2, 65.5, 68.7, 75.0, 98.9, 102.0, 126.0, 128.1, 128.9, 137.0, 193.8.
Preparation of methyl 3-S-acetyl-2-azido-2-deoxy-3-thio-α- D-mannopyranoside (2)
A mixture of the compound 1 (5.4 g; 14.7 mmol) and 50% aqueous acetic acid (60 mL) was heated at 100°C for 2 h, by which time the reaction mixture was homogeneous. The resulting yellow solution was cooled and concentrated. The residue was purified by putting it through a short plug of silica gel (the byproducts were removed by eluting the silica gel with diethyl ether/hexane (2:1); the desired product was eluted with ethyl acetate). Yield of the diol, obtained as a pale yellow solid, was 3.5 g (82%). Preparation of 1,4,6-tri-o-acetyl-3-S-acetyl-2-azido-2- deoxy-3-thio-α-D-mannopyranose (3)
A solution of the diol 2 (11.25 g; 40.6 mmol) in acetic anhydride (120 mL) and acetic acid (120 mL) was chilled to 0°C prior to the addition of concentrated sulphuric acid (1 mL) dropwise over a 30 minute period. The ice bath was removed after 2 h and stirring was
continued for 18 h. Sodium acetate (12 g) was added and after 15 minutes the reaction mixture was diluted with toluene (200 mL) and then evaporated to dryneβs. The residue was partitioned between diethyl ether (200 mL) and water (100 mL); the organic phase was washed with water (5 x 20mL), dried, and concentrated to give a pale yellow gum which solidified under high vacuum (13.5 g; 85%). A small portion of the product was recrystallized (ethyl
acetate/hexanes) for analytical purposes; m.p. 87.5-88°.
1H NMR (CDCl3; δ (ppm) relative to TMS): 2.03, 2.09, 2.21 (s, 3x3H, OCOCH3), 2.38 (SAc), 3.85 (d, J 1.3 Hz, 1H), 4.00-4.11 (m, 2H), 4.17-4.26 (m, 2H), 5.19 (dd, J 10.5, 10.5 Hz, 1H, H-4), 6.18 (s, 1H, H-1). 13C NMR (CDCl3;
δ(ppm) relative to TMS): 20.5, 20.6, 20.9, 30.6, 45.1,
62.0, 62.9, 64.1, 71.9, 90.9, 168.4, 169.3, 170.6, 193.8. IR (KBr) vmaxcm-1 2112 (m), 1750 (s), 1715 (m), 1370 (m), 1225 (s). [α]D 5° (c, 1.07%, CHCl3).
Preparation of 1,4,6-tri-o-acetyl-2-deoxy-2',3'-dihydro-2'- methylthiooxazolo-[2,3-d]-3-thio-α-D-mannopyranose (4)
A stirring solution of the azide 3 (13.5 g; 34.7 mmol) in dry dichloromethane (200 mL) was cooled to -78°C prior to the slow addition of a solution of
triphenylphosphine (9.1 g; 34.7 mmol) in dry
dichloromethane (200 mL) over a 2 h period. The reaction mixture was allowed to warm up to room temperature and stirring was continued for 18 h. The resulting solution was concentrated under vacuum before chromatographic separation (silica gel; eluting with ethyl acetate/hexane (1:3)) of the product from triphenylphosphine oxide.
Colourless needles of the pure product were obtained by recrystallization from ethyl acetate/ hexane, 5.3 g (44%); m.p. 139 - 140°C (lit mp. Tetrahedron Letters, 1981 22 933, 135°C). 1H NMR (CDCl3; 6(ppm) relative to TMS): 2.00, 2.03, 2.10
(s, 3x3H, OCOCH3); 2.24, (app. d, J 2Hz, 3H, N=C-CH3); 3.75 (dd, 1H, J3,2 6.2 Hz, J3,4 10.0 Hz, H-3); 3.91 (ddd, 1H, J5,4 10.2 Hz, J5,6 5.3 Hz, J5,6, 2.9 Hz, H-5), 3.99 (dd, 1H, J6,6, 12.2 Hz, J6,5 5.3 Hz, H-6), 4.05 (dd, 1H, J2,3 6.2 Hz, J2,1 2 Hz, H-2), 4.10 (dd, 1H, J6,,6 12.2 Hz, J6,,5 2.9 Hz, H-6'),
4.80 (dd, 1H, J4,3 10.0 Hz, J4,5 10.2 Hz, H-4), 6.76 (br s, 1H, H-1) : 13C NMR (CDCl3; δ (ppm) relative to TMS) 20.6, 20.77, 20.82, 52.0, 62.4 (C6), 68.7, 69.9, 77.9, 91.1 (Cl), 168.3, 168.4, 169.4, 170.6. Anal, calculated for C14H19NO7S : C48.67; H, 5.54; N, 4.06. Found : C, 48.77; H, 5.64; N,
3.93. [α]D -57° (c, 1.22%, CHCl3).
Preparation of 2-deoxy-2',3'-dihydro-2'-methylthiooxazolo- [2,3-d]-3-thio-α,β-D-mannopyranose (5)
A mixture of the triacetate 4 (10 g; 29 mmol) and Amberlite IRA 400 (OH-) (10 g) in methanol (250 mL) was stirred at room temperature for 48 h. The filtrate obtained after resin removal was concentrated to a solid (5.4 g; 86%); m.p. 185-189°C (lit mp, Tetrahedron Letters, 1981 22 933, 192-195°C). The triol (5) was used in the next step without further purification.
Alternatively, compound 4 can be deacetylated using a solution of sodium methoxide in methanol, in similar yield, following the literature method of Brossmer and Mack (Tetrahedron Letters, 1981 22 933). 13C NMR (d6-DMSO; δ(ppm) relative to TMS): 19.2, 56.2, 63.8, 72.0, 78.4, 89.6, 101.3, 165.9
Preparation of 2-acetamido-2,3-dideoxy-5,6-o- isopropylidene-3-thio-D-mannofuranose (7)
This compound was prepared from the triol 5 following the literature method of Brossmer and Mack (Tetrahedron Letters, 1987 28 191).
1H NMR of 2-deoxy-2',3'-dihydro-5,6-o-isopropylidene-2'- methylthiooxazolo-[2,3-d]-3-thio-β-D-mannofuranose (6) (CDCl3; δ(ppm) relative to TMS): 1.35, 1.41 (s, 2x3H,
C(CH3)2); 2.22 (s, 3H, N=C-CH3); 3.96 (dd, 1H, J6,,6 8.3 Hz,
J6,,5 4.6 Hz, H-6'); 4.12 (dd, 1H, J6,6, 8.3 Hz, J6,5 5.8 Hz, H-6), 4.24 (ddd, 1H, J5,6 5.8 Hz, J5,6, 4.6 Hz, J5,4 8.5 Hz, H-5), 4.38 (dd, 1H, J4,5 8.5 Hz, J4,3 5.6 Hz, H-4), 4.57 (dd, 1H, J3,4 5.6 Hz, J3,2 8.6 Hz, H-3), 5.12 (dd, 1H, J2,3 8.6 Hz, J2,1 1.5 Hz, H-2), 5.47 (d, 1H, J1,2 1.5 Hz, H-1).
1H NMR of 7 (CDCI3/CD3OD; δ(ppm) relative to TMS): 5.53 (s, 1H, H-1β); 5.28 (d, 1H, H-1α))
Preparation of 5-acetamido-5,6-dideoxy-6-thio-D-glycero-β- D-galacto -non-2-ulo-pyranosonic acid (9)
To an ice-cooled slurry of oxalacetic acid (3.75 g; 28.39 mmol) in water (13 mL) was added a solution of sodium hydroxide (2.27 g; 56.75 ramol) in water (12 mL) resulting in a solution of pH 7 - 7.5. The oxalacetate solution and nickel acetate tetrahydrate (0.94 g; 3.78 mmol) were added to the compound 7 (3.42 g; 9.46 mmol) and the mixture stirred at room temperature for 16 h.
Amberlite IR-120 (H+) resin was added to pH 3. After stirring for six h, the resin was filtered off and the filtrate was lyophilised. The residue was purified by column chromatography (Amberlite IRA-400 (HCOO- form) eluting with formic acid (2N) ) affording the diacid 8 (2.38 g; 68%) (Brossmer and Mack, Tetrahedron Letters, (1987) 28 191 and H. Hagedorn et al, Carbohydrate Research, 1992 236 89).
1H NMR (D2O; δ (ppm) relative to HOD = 4.7): 2.04 (s, 3H, Ac); 3.36 (d, 1H, J3,4 10.2 Hz, H-3); 3.47 - 3.57 (m, 3H, H-6, H-8, H-9'); 3.76 (m, 1H, H-9); 3.91 (m, 1H, H-7); 4.10 (pseudo triplet, 1H, J4,5 9.9 Hz, H-4); 4.18 (pseudo
triplet, 1H, J5 , 6 10.5 Hz, J5,NH 10.5 Hz, H-5). 13C NMR (D2O; δ(ppm) relative to TMS): 25.8 (NHCOCH3); 48.0 (C6); 59.1 (C-5); 62.3 (C-3); 66.7 (C-9); 72.0 (C-8); 73.7 (C-4); 74.6 (C-7); 85.5 (C-2); 176.3, 177.2, 178.8 (carbonyls).
A solution of the diacid 8 (2.38 g; 6.45 mmol) in water (200 mL) was adjusted to pH 6 with 0.1M Na2HPO4 solution and heated at 90°C for 5 - 6 h. The resulting solution was then purified on Amberlite IRA-400 (HCOO- form) eluting successively with water (1 litre) and HCOOH (2N). The latter fraction was lyophilised, affording compound 9 as a solid (1.62 g; 77%).
1H NMR (D2O; δ (ppm) relative to HDO = 4.7): 2.03 (s, 3H, NHCOCH3); 2.24 (dd, 1H, J3a,3e 11.2 Hz, J3a,413.3 Hz, H-3a);
2.46 (dd, 1H, J3e,4 4.4 Hz, H-3e); 3.42 (dd, 1H, J6,5 10.1 Hz, J6 , 7 1.6 Hz, H-6); 3.54 (dd, 1H, J9, , 8 5.8 Hz, J9,,9 10.1 Hz, H-9'); 3.60 (ddd, 1H, J8,7 9.2 Hz, J8 , 9 5.1 Hz, H-8); 3.75 (dd, 1H, H-9); 3.83 (dd, 1H, H-7); 3.92 (ddd, 1H, J4 , 5 10.7 Hz, H-4); 4.03 (pseudo triplet, 1H, H-5). 13C NMR
(D2O; δ(ppm) relative to TMS): 24.6 (NHCOCH3); 46.9 (C-3); 47.2 (C-6); 58.4 (C-5); 63.2 (C-9); 70.9, 71.3 (C-4, C-7); 73.4 (C-8); 83.8 (C-2); 177.6 (carbonyls).
Preparation of methyl 5-Acetamido-5,6-dideoxy-6-thio-D- glycero-β-D-galacto-non-2-ulo-pyranosonate (10)
Dowex 50W-X8 (H+) (2 mL) was added to a solution of the acid 9 (2.16 g; 6.65 mmol) in dry methanol (200 mL) and the mixture was stirred at room temperature for 48 h.
The resin was filtered off and the filtrate concentrated giving the ester 10 as a solid (1.91 g; 85%).
1H NMR (D2O; δ (ppm) relative to HOD = 4.7): 2.03 (s, 3H, NHCOCH3); 2.24 (dd, 1H, J3a,3e 13.1 Hz, J3a,4 11.3 Hz, H-3a); 2.49 (dd, 1H, J3e,4 4.4 Hz, H-3e); 3.50 - 3.59; 3.70 - 3.85 (m, 8H, H-5, H-6, H-8, H-9, H-9', COOCH3); 3.92 (ddd, 1H, J4,5 10.8 Hz, H-4); 4.02 (pseudo triplet, 1H, J5 , 6 10.2 Hz, H-5). 13C NMR (D2O; δ (ppm) relative to TMS): 24.7
(NHCOCH3), 46.5 (C-3), 47.3 (C-6), 56.5, 58.4 (C-5,
COOCH3), 65.7 (C-9), 71.0, 71.1, 73.5 (C-4, C-7, C-8) 83.2 (C-2), 175.4, 177.7 (carbonyls). MS (FAB): 340 (M+1)+. MS (High Resolution FAB for C12H22NO8S) : 340.1066 (calculated); 340.1075 (observed).
Preparation of methyl 7,8,9-tri-o-acetyl-2,3,5,6- tetradeoxy-4',5'-dihydro-2'-methyloxazolo[5,4-d]-6-thio-D- glycero-β-D-talo-non-2-enopyranosonate (11)
Concentrated sulphuric acid (0.4 mL) was added to a solution of the ester 10 (0.973 g; 2.87 mmol) in acetic anhydride (4 mL) and glacial acetic acid (4 mL), and the resulting solution stirred at room temperature for 40 h. The solution was poured into a stirred saturated solution
of sodium bicarbonate, stirred for 1 h before extraction with ethyl acetate. The extracts were dried (Na2SO4) and concentrated to afford the oxazoline 11 as a syrup (1.2g; 97%); 95% pure, by 1H NMR. This was used in the subsequent step without further purification.
1H NMR (CDCl3; δ (ppm) relative to TMS): 2.04, 2.09, 2.11, 2.15 (s, 4 x 3H, OCOCH3, oxazoline CH3); 2.75 (dd, 1H, J6 , 5 10.7 Hz, J6,7 2.9 Hz, H-6); 3.84 (s, 3H, COOCH3); 4.14 (dd, 1H, J9,8 6.3 Hz, J9,9, 12.2 Hz, H-9); 4.25 (dd, 1H, J5 , 4 9.4 Hz, H-5); 4.37 (dd, 1H, J9,,8 3.2 Hz, H-9'); 4.89 (dd, 1H, J4,3 3.5 Hz, H-4); 5.42 (ddd, 1H, J8,7 5.9 Hz, H-8); 5.77 (dd, 1H, H-7); 7.20 (d, H-3). 13C NMR (CDCl3; δ (ppm) relative to TMS): 14.0, 20.5, 20.6, 20.8 (s, 4 x 3H, =C- CH3, COCH3); 47.0 (C-6); 52.8 (COOCH3); 61.7 (C-9); 67.5 (C-5); 69.2 (C-7); 70.8 (C-8); 75.8 (C-4); 129.9 (C-3); 131.8 (C-2); 163.8, 165.9, 169.5, 169.8, 170.5 (N=C-, carbonyls). MS (FAB): 430 (M+1)+. MS (High Resolution FAB for C18H24NO9S) : 430.1172 (calculated); 430.1189
(observed). [α]D-47º (c, 1.37%, CHCl3). Preparation of methyl 5-acetamido-7,8,9-tri-o-acetyl-4- azido-2,3,4,5,6-pentadeoxy-6-thio-D-glycero-D-galacto-non- 2-enopyranosonate (12)
The oxazoline 11 (1.04 g; 2.42 mmol) was treated with azidotrimethylsilane (0.96 mL; 7.26 mmol) in 2-methyl- 2-propanol (10 mL) at 75 - 80°C for 48 h. The solution was cooled, added to saturated sodium bicarbonate, and after 1 h, extracted with ethyl acetate (3 x 50 mL). The extracts were dried (Na2SO4) and solvent removal gave a syrup
(1.01 g). This was purified by column chromatography on silica gel, by elution with ethyl acetate / hexane (3:1), which afforded the azide 12 as a foam (0.75g; 66%).
1H NMR (CDCl3; δ(ppm) relative to TMS): 2.04, 2.06, 2.10, 2.11 (s, 4 x 3H, NHCOCH3, COCH3); 3.82 (s, 3H, COOCH3);
3.85 (dd, 1H, J6 , 5 6.4 Hz, J6 , 7 4.8 Hz, H-6); 4.01 (ddd, 1H,
J5,4 6.9 Hz, J5,NH 7.9 Hz, H-5); 4.16 (dd, 1H, J9,,8 5.8 Hz, J9,,9 12.2 Hz, H-9'); 4.36 (dd, 1H, J9,8 3.7 Hz, H-9); 4.67 (dd, 1H, J4,3 3.9 Hz, H-4); 5.37 (ddd, 1H, J8,7 6.1 Hz, H- 8); 5.49 (dd, 1H, H-7); 6.01 (d, 1H, NH); 6.83 (d, 1H, H- 3) . 13C NMR (CDCl3; d(ppm) relative to TMS) : 20.5, 20.7,
23.1 (OCOCH3, NHCOCH3); 43.4 (C-6); 46.8 (C-5); 52.9
(COOCH3); 59.0 (C-4); 61.5 (C-9); 68.2 (C-7); 69.8 (C-8); 127.7 (C-3); 129.1 (C-2); 163.4, 169.6, 169.9, 170.5, 170.6 (carbonyls) . IR (NaCl) vmax (cm-1) : 2104 (-N3) . MS (FAB) : 473 (M+1)+, 430 (M+-N3) . MS (High Resolution FAB for
C18H25N4O9S) : 473.1342 (calculated); 473.1339 (observed). [α]D 73º (c, 0.31%, CHCI3) .
Preparation of ammonium 5-acetamino-4-amino-2,3,4,5,6- pentadeoxy-6-thio-D-glycero-D-galacto-non-2-enopyranosonate (14)
A mixture of the azide 12 (126 mg; 0.267 mmol), zinc dust (69.7 mg; 1.067 mmol) and 2N HCl (2 mL) was heated at 75°C for 45 min. The resulting solution was concentrated to dryness yielding the amine hydrochloride, 5-acetamido-4-ammonium-2,3,4,5,6-pentadeoxy-6-thio-D- glycero -D-galacto-non-2-enopyranosonate (13), as a straw coloured foam (140 mg).
To the foam in water (5 mL) was added sodium hydroxide to pH 13 and the solution stirred at room
temperature for 16 h. The pH was adjusted to 7.5 using Dowex 50W-X400 (H+). The resin was filtered off and the filtrate purified on a Dowex 50W-X400 (H+) column. The column was washed with water (200 mL), and then eluted with 1.5N NH4OH solution; the latter fraction afforded the amine 14 (57 mg; 66%) as a foam after lyophilisation.
1H NMR (D2O; δ (ppm) relative to HOD = 4.7): 2.00 (s, 3 H, NHCOCH3), 3.52 (dd, 1 H, J9,,8 5.8 Hz, J9,,9 11.4 Hz, H-9'); 3.63 (m, 1 H, H-8); 3.68-3.83 (m, 3 H, H-4, H-6, H-9), 4.08 (pseudo doublet, J7,8 8.8 Hz, H-7), 4.29 (pseudo triplet, 1 H, J5,4 9.5 Hz, J5,6 9.5 Hz, H-5); 6.34 (br s, 1 H, H-3).
13C NMR (D2O; external reference CHCl3) : 24.8 (NHCOCH3);
47.1 (C-6); 51.5 (C-5); 54.7 (C-4); 65.5 (C-9); 70.9 (C-8); 73.5 (C-7); 124.0 (C-3); 139.1 (C-2); 172.4; 177.4 (C-1, NHCOCH3) * tentative assignments A small amount of the amine 14 was desalted
(HPLC; Waters Millipore μBondapak C18 reverse phase;
eluant: 0.1% TFA in H2O) to give the corresponding acid, for microanalytical and NMR characterisation purposes. 1H NMR (D2O; δ (ppm) relative to HOD = 4.7): 2.09 (s, 3 H, NHCOCH3); 3.62 (dd, 1 H, J9 , , 8 5.6 Hz, J9,,9 = 11.6 Hz, H- 9'); 3.72 (m, 1 H, H-8); 3.82 (pseudo doublet, 1 H, H-9); 3.86, 3.94 (pseudo doublet x 2, 1 H x 2, J 9.8 Hz and 9.5 Hz, respectively, H-4, H-6); 4.29 (dd, 1 H, J7 , 6 2.5 Hz, J7,8 9.4 Hz, H-7); 4.45 (pseudo triplet, 1 H, J5,4 10.0 Hz, J5 , 6 10.0 Hz, H-5); 6.61 (br s, 1 H, H-3).
MS (FAB): 307 (M+1)+, 290 (M+ - NH2). MS (High Resolution FAB for C11H19N2O6S): 307.0964 (calculated); 307.0974
(observed). Anal. calculated for C11H18N2O6S: C, 27.59; H, 4.03; N, 4.17. Found: C, 27.52; H, 4.06; N, 4.20. [α]D 18º (c, 1.42%, H2O)
The amine hydrochloride 13 was characterised as its peracetate. Thus, the azide 12 (47.5 mg; 0.10 mmol) was treated with zinc dust and 2N HCl as described above. The crude amine hydrochloride 13 was then treated with acetic anhydride (1 mL) and concentrated sulphuric acid
(0.1 mL) at room temperature for 16 h before pouring into saturated sodium bicarbonate solution. After extraction with acetonitrile (5 x 10 mL) and solvent removal, an oil (39 mg) was obtained. This was chromatographed (silica gel; eluting with ethyl acetate/methanol (19:1)), affording methyl 5,6-diacetamido-7,8,9-tri-o-acetyl-2,3,4,5,6- pentadeoxy-6-thio-D-glycero-β-D-gaIacto-non-2- enopyranosonate (25 mg; 60%) as a syrup.
1H NMR (CDCl3; δ (ppm) relative to TMS): 1.95; 2.00 2.06, 2.07, 2.11 (s, 5 x 3H, Ac); 3.66 (dd, 1H, J6,5 8.9 Hz, J6,7 4.6 Hz, H-6); 3.80 (s, 3H, COOCH3); 4.15 (dd, 1H, J9,,8 5.8 Hz, J9,,9 12.4 Hz, H-9'); 4.38 (dd, 1H, J9,8 3.5 Hz, H-9); 4.38 (m, 1H, H-5); 4.85 (ddd, 1H, J4,3 3.0 Hz, J4,5 9.1 Hz, J4,NH 9.1 Hz, H-4); 5.21 (ddd, 1H, J8,7 6.3 Hz, H-8); 5.52 (dd, 1H, H-7); 6.16; 6.41 (d, 2 x 1H, NH); 6.70 (d, 1H, H- 3). 13C NMR (CDCl3; d(ppm) relative to TMS): 20.5, 20.7, 20.9, 23.0 (OCOCH3, NHCOCH3); 44.3 (C-6); 49.3, 50.4 (C-4, C-5); 52.9 (COOCH3); 61.6 (C-9); 67.6, 70.3 (C-7, C-8);
128.1 (C-2); 131.1 (C-3); 163.6, 169.9, 170.6, 171.0
(carbonyls). MS (FAB): 489 (M+1)+. MS (High Resolution FAB for C20H29N2O10S) : 489.1543 (calculated); 489.1542
(observed). [α]D -13º (c, 0.40%, CHCl3). Preparation of ammonium 5-acetamido-2,2,4,5,6-pentadeoxy-4- quanidino-6-thio-D-glycero-β-D-galacto-non-2- enopyranosonate (15)
To a solution of the amine 14 (40.0 mg; 0.124 mmol) and imidazole (33.8 mg; 0.496 mmol) in water (1mL) was added pyrazole carboxamidine hydrochloride (33.4 mg;
0.248 mmol). The solution was stirred at 60°C for 24 h and then chromatographed (silica gel; eluting with 80%
isopropanol) to provide compound 15 (25 mg; 55%).
1H NMR (D2O; δ (ppm) relative to HDO = 4.7): 1.96 (s, 3 H, NHCOCH3), 3.53 (dd, 1 H, J9,,8 5.7 Hz, J9,,9 11.6 Hz, H-9');
3.63 (m, 1 H, H-8), 3.73-3.86 (m, 3 H, H-4, H-6, H-9), 4.22 (pseudo triplet, 1 H, J5,4 9.3 Hz, J5,6 9.3 Hz, H-5), 4.40 (pseudo doublet, 1 H, J7,8 8.6 Hz, H-7), 6.32 (br s, 1 H, H-3). 13C NMR (D2O; external reference CHCl3) : 24.7 (NHCOCH3);
47.1 (C-6); 53.2 (C-5); 56.2 (C-5); 65.8 (C-9); 71.4 (C-7); 73.8 (C-8); 130.0 (C-3); 137.6 (C-2); 159.7 (C-10
guanidinium group); 173.1; 177.4 (C-1, NHCOCH3) * tentative assignments
A small sample of the guanidium compound 15 was desalted (HPLC; Waters Millipore μBondapak C18 reverse phase; eluant: 0.1% TFA in H2O) to give the corresponding acid of 15. 1H NMR (D2O; δ(ppm) relative to HDO = 4.7): 1.98 (s, 3 H, NHCOCH3); 3.59 (dd, 1 H, J9,8 5.0 Hz, J9,,9
11.3 Hz, H-9'); 3.68 (m, 1 H, H-8); 3.81 (dd, 1 H, J9,8 1.1 Hz, H-9); 3.84, 3.92 (pseudo doublet x 2, 1 H x 2, J 9.2 Hz, 9.2 Hz, H-4, H-6), 4.30 (pseudo triplet, 1 H, J5,4 9.2 Hz, J5,6 9.2 Hz, H-5); 4.48 (dd, 1 H, J7,6 1.9 Hz, J7,8 8.8 Hz, H-7); 6.54 (br s, 1 H, H-3). MS (FAB): 349 (M+1)+. MS (High Resolution FAB for C12H21N4O6S) : 349.1182
(calculated); 349.1164 (observed).
Example 3 Biological Evaluation
Sialidase activity was assayed using the fluorimβtric assay of Potier et al (Anal. Biochem., (1979), 94 287), as modified by Chong et al (Biochim. Biophys.
Acta, 1991 1077 65). The concentration of the substrate, 4-methylumbelliferyl Neu5Ac, was 80mM.
IC50 (M)
Compound 14 1 x 10-6
Compound 15* 5 x 10-9
This compound was found to be a slow binding inhibitor.
Example 4
The following formulations are representative of compositions according to the invention:
Aqueous Solution % w/w
Compound of formula (I) 10.0
Benzalkonium chloride 0.04
Phenylethyl alcohol 0.40
Purified water to 100% w/w
Aqueous Cosolvent Solution % w/w
Compound of formula (I) 10 .0
Benzalkonium chloride 0 .04
Polyethylene glycol 400 10 .0
Propylene glycol 30 .0
Purified water to 100% w/w
Aerosol Formulation %w/w
Compound of formula (I) 7 .5
Lecithin 0 .4
Propellant 11 25 .6
Propellant 12 66 .5
Dry Powder Formulation % w/w
Compound of formula (I) 40 .0
Lactose 60 .0 These formulations are prepared by admixture of the active ingredient and excipients by conventional pharmaceutical methods.
It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.
Claims
1. A compound of formula (I)
SO3H, tetrazol, CH2CHO, CHO, or CH(CHO)2; one of R2 and R3 is OH, (alk)xNR6R7, CN or N3, and the other is hydrogen, where alk is unsubstituted or substituted methylene, and x is 0 or 1, with the proviso that when R2 or R3 is OH R1 cannot be COOH;
R4 is methyl, in which one or more hydrogens is optionally replaced by a substituted or unsubstituted
C1-4alkyl or aryl group, or by a halogen;
R5 is CHOR9CHOR9CH2OR9;
R6 is hydrogen, C1-6alkyl, allyl, aryl, aralkyl, ami dine, NR7R8, or an unsaturated or saturated ring
containing one or more heteroatoms;
R7 is hydrogen, C1-6alkyl, or allyl, or NR6R7 forms an optionally substituted 5 or 6 membered ring optionally containing one or more additional heteroatoms, or R6 and R7 may be the same; and
R8 is hydrogen or C1-6alkyl; and
each R9 is the same or different, and is hydrogen; an acyl group having 1 to 4 carbon atoms; a linear or cyclic alkyl group having 1 to 6 carbon atoms, or a halogen-substituted analogue thereof; an allyl group or an unsubstituted aryl group; or an aryl substituted by a halogen, an OH group, an NO2 group, an NH2 group or a COOH group;
and pharmaceutically acceptable salts of the compounds of formula (I) and pharmaceutically acceptable derivatives thereof.
2. A compound according to Claim 1, wherein R1 is COOH and R2 is H.
3. A compound according to Claim 1 or Claim 2, wherein R3 is NR6R7,
4. A compound according to Claim 3, wherein R3 is NH2 or guanidino.
5. A compound according to any one of Claims 1 to 4, wherein R4 is methyl or halogen-substituted methyl.
6. A compound according to any one of Claims 1 to 5, wherein R4 is methyl.
7. A compound according to any one of Claims 1 to 5, wherein R4 is FCH2, F2CH or CF3.
8. A compound according to any one of Claims 1 to 7, wherein R9 is H or acetyl.
9. A compound of formula (la)
wherein R3 is hydrogen, OH, (alk)xNR6R7, CN or N3, where alk is unsubstituted or substituted methylene, and x is 0 or 1;
R4 is methyl, in which one or more hydrogens is optionally replaced by a substituted or unsubstituted
C1-4alkyl or aryl group, or by a halogen;
R5 is CHOR9CHOR9CH2OR9 ;
R6 is hydrogen, C1-6alkyl, allyl, aryl, aralkyl, amidine, NR7R8, or an unsaturated or saturated ring
containing one or more heteroatoms;
R7 is hydrogen, C1-6alkyl, or allyl, or NR6R7 forms an optionally substituted 5 or 6 membered ring optionally containing one or more additional heteroatoms, or R6 and R7 may be the same; and R8 is hydrogen or C1-6alkyl; and
each R9 is the same or different, and is hydrogen; an acyl group having 1 to 4 carbon atoms; a linear or cyclic alkyl group having 1 to 6 carbon atoms, or a halogen-substituted analogue thereof; an allyl group or an unsubstituted aryl group; or an aryl substituted by a halogen, an OH group, an NO2 group, an NH2 group or a COOH group;
and pharmaceutically acceptable salts and
derivatives thereof.
10. A compound of formula II
and physiologically acceptable derivatives and solvates thereof.
11. 5-Acetamido-2,3,4,5,6-pentadeoxy-4-guanidino-6- thio-D-glycero-β-D-galacto-non-2-enopyranosonate or a pharmaceutically-acceptable salt thereof.
12. Ammonium 5-acetamido-2,3,4,5,6-pentadeoxy-4- guanidino-6-thio-D-glycero-β---galacto-non-2- enopyranosonate.
13. 5-Acetamido-4-amino-2,3,4,5,6-pentadeoxy-6-thio- D-glycero-D-galacto-non-2-enopyranosonate.
14. Ammonium 5-Acetamido-4-amino-2,3,4,5,6- pentadeoxy-6-thio-D-glycero-D-galacto-non-2- enopyranosonate.
15. 5-Acetamido-4-azido-2,3,4,5,6-pentadeoxy-6-thio- D-glycero-D-galacto-non-2-enopyranosonate.
16. Methyl 5-Acetamido-4-azido-2,3,4,5,6-pentadeoxy- 6-thio-D-glycero-D-galacto-non-2-enopyranosonate.
17. A compound according to any one of Claims 1 to 16 for use in medicine.
18. A compound according to any one of Claims 1 to 16, for use as an active therapeutic agent in the treatment of viral infections selected from orthomyxovirus infection or paramyxovirus infection.
19. Use of a compound according to any one of
Claims 1 to 16 for the manufacture of a medicament for the treatment of a viral infection.
20. Use according to Claim 19 in which the viral infection is an orthomyxovirus infection or a paramyxovirus infection.
21. Use according to Claim 19 or Claim 20 in which the viral infection is influenza.
22. A method for the preparation of a compound of formula (I) as defined in claim 1, which comprises the steps of subjecting a 2,3,5,6-tetradeoxy-4',5'-dihydro-2'- methyloxazolo[5,4-D-6-thio-D-glycero-β-D-talo-non-2- enopyranosonate to hydrolysis to give a compound of general formula (III),
wherein R1, R4 and R5 are as defined in general formula (I), and OL is a leaving group and reacting the compound of formula (III) with an appropriate nucleophile.
23. A method according to Claim 33 wherein methyl 7,8,9-tri-o-acetyl-2,3,5,6-tetradeoxy-4',5'-dihydro-2'- methyloxazolo [5,4-d]-6-thio-D-glycero-β-D-talo-nonn2- enopyranosonate is hydrolysed.
24. A pharmaceutical formulation comprising a
compound according to any one of Claims 1 to 16, together with a pharmaceutically-acceptable carrier.
25. A formulation acocrding to Claim 24 adapted for administration to the respiratory tract.
26. A formulation according to Claim 24 adapted for intranasal administration.
27. A method for the treatment of viral infection in an animal comprising the step of administration of an effective amount of a compound according to any one of Claims 1 to 16 to an animal in need of such treatment.
28. A method according to Claim 27, wherein the compound is as defined in any one of Claims 9 to 16.
29. A method according to Claim 28, wherein the compound is as defined in any one of Claims 10 to 16.
30. A method according to any one of Claims 27 to 29, wherein the viral infection is infection by an
orthomyxovirus or a paramyxovirus.
31. A method according to Claim 30, wherein the viral infection is influenza.
32. A method according to Claim 30 or Claim 31, wherein the animal is a human.
33. A method according to any one of Claims 27 to 32 wherein the compound is administered to the respiratory tract.
34. A method according to any one of Claims 27 to 32 wherein the compound is administered intranasally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31055/95A AU3105595A (en) | 1994-08-03 | 1995-08-03 | 2,6-dideoxy-2,3-didehydro-6-thio derivatives of alpha-d-neuraminic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPM7257A AUPM725794A0 (en) | 1994-08-03 | 1994-08-03 | Chemical compounds |
AUPM7257 | 1994-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004265A1 true WO1996004265A1 (en) | 1996-02-15 |
Family
ID=3781779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1995/000470 WO1996004265A1 (en) | 1994-08-03 | 1995-08-03 | 2,6-DIDEOXY-2,3-DIDEHYDRO-6-THIO DERIVATIVES OF α-D-NEURAMINIC ACID |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPM725794A0 (en) |
WO (1) | WO1996004265A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763483A (en) * | 1995-12-29 | 1998-06-09 | Gilead Sciences, Inc. | Carbocyclic compounds |
US5859284A (en) * | 1996-08-23 | 1999-01-12 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
US5866601A (en) * | 1995-02-27 | 1999-02-02 | Gilead Sciences, Inc. | Carbocyclic compounds |
US5886213A (en) * | 1997-08-22 | 1999-03-23 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
US5952375A (en) * | 1995-02-27 | 1999-09-14 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
US5994377A (en) * | 1996-10-21 | 1999-11-30 | Gilead Sciences, Inc. | Piperidine compounds |
EP0976734A2 (en) * | 1995-02-27 | 2000-02-02 | Gilead Sciences, Inc. | Selective inhibitors of viral or bacterial neuraminidase |
US6111132A (en) * | 1997-12-12 | 2000-08-29 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
US6518438B2 (en) | 1996-08-23 | 2003-02-11 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
WO2018213933A1 (en) * | 2017-05-25 | 2018-11-29 | The Governors Of The University Of Alberta | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7759091A (en) * | 1990-04-24 | 1991-11-11 | Biota Scientific Management Pty Ltd | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
-
1994
- 1994-08-03 AU AUPM7257A patent/AUPM725794A0/en not_active Abandoned
-
1995
- 1995-08-03 WO PCT/AU1995/000470 patent/WO1996004265A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7759091A (en) * | 1990-04-24 | 1991-11-11 | Biota Scientific Management Pty Ltd | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Non-Patent Citations (1)
Title |
---|
TETRAHEDRON LETTERS, Vol. 28, No. 2, 1987, H. MACK and R. BROSSNER, "Synthesis of 6- Thiosialic Acids and 6- Thio- N-Acetyl -D- Neuraminic Acid", pages 191-194. * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0976734A2 (en) * | 1995-02-27 | 2000-02-02 | Gilead Sciences, Inc. | Selective inhibitors of viral or bacterial neuraminidase |
US6225341B1 (en) | 1995-02-27 | 2001-05-01 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
US5866601A (en) * | 1995-02-27 | 1999-02-02 | Gilead Sciences, Inc. | Carbocyclic compounds |
US5952375A (en) * | 1995-02-27 | 1999-09-14 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
EP0976734A3 (en) * | 1995-02-27 | 2000-03-22 | Gilead Sciences, Inc. | Selective inhibitors of viral or bacterial neuraminidase |
US5763483A (en) * | 1995-12-29 | 1998-06-09 | Gilead Sciences, Inc. | Carbocyclic compounds |
US6057459A (en) * | 1996-08-23 | 2000-05-02 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
US6204398B1 (en) | 1996-08-23 | 2001-03-20 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
US5859284A (en) * | 1996-08-23 | 1999-01-12 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
US6518438B2 (en) | 1996-08-23 | 2003-02-11 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
US5994377A (en) * | 1996-10-21 | 1999-11-30 | Gilead Sciences, Inc. | Piperidine compounds |
US6376674B1 (en) | 1996-10-21 | 2002-04-23 | Gilead Sciences, Inc. | Piperidine compounds |
US5886213A (en) * | 1997-08-22 | 1999-03-23 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
US6111132A (en) * | 1997-12-12 | 2000-08-29 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
WO2018213933A1 (en) * | 2017-05-25 | 2018-11-29 | The Governors Of The University Of Alberta | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase |
AU2018273411B2 (en) * | 2017-05-25 | 2022-12-01 | The Governors Of The University Of Alberta | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase |
US11773129B2 (en) * | 2017-05-25 | 2023-10-03 | The Governors Of The University Of Alberta | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase |
Also Published As
Publication number | Publication date |
---|---|
AUPM725794A0 (en) | 1994-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5360817A (en) | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents | |
EP0539204B1 (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid | |
US5919819A (en) | Dihydropyran derivatives as viral neuraminidase inhibitors | |
WO1995020583A1 (en) | Derivatives of 2-deoxy-2,3-dehydro-n-acetylneuraminic acid (dana) | |
AU774222B2 (en) | Dimeric compounds and their use as inhibitors of neuraminidase | |
US5990156A (en) | 6-Carboxamido dihydropyran derivatives | |
WO1995018800A1 (en) | Derivatives of 2-deoxy-2,3-dehydro-n-acetylneuraminic acid (dana) | |
WO1996004265A1 (en) | 2,6-DIDEOXY-2,3-DIDEHYDRO-6-THIO DERIVATIVES OF α-D-NEURAMINIC ACID | |
US5639786A (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of α-D-neuraninic acid | |
KR20050044337A (en) | Dimeric compounds and their use as anti-viral agents | |
JP3923081B6 (en) | Dihydropyran derivatives as viral neuraminidase inhibitors | |
KR100942493B1 (en) | Dimeric compounds and their use as anti-viral agents | |
AU6613690A (en) | Anti-viral compounds that bind the active site of influenza neuramidase and display (in vivo) activity against orthomyxovirus and paramyxovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |